现代中西医结合杂志
現代中西醫結閤雜誌
현대중서의결합잡지
MODERN JOURNAL OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE
2015年
15期
1621-1624
,共4页
益肾疏肝活络方%恩替卡韦%肝纤维化
益腎疏肝活絡方%恩替卡韋%肝纖維化
익신소간활락방%은체잡위%간섬유화
Yishen Shugan Tongluo Recipe%entecavir%hepatic fibrosis
目的：观察益肾疏肝活络方联合恩替卡韦治疗肾虚血瘀型慢性乙肝肝纤维化的临床疗效。方法将120例慢性乙肝肝纤维化患者随机分为2组，治疗组60例给予益肾疏肝活络方联合恩替卡韦治疗，对照组60例给予合恩替卡韦，疗程均为4周。2组分别于治疗前及治疗24，48周后检测 HBV DNA转阴率、肝功能、血清肝纤维化指标、血常规、肾功能、尿常规，并于治疗前及48周结束后行肝脏穿刺病理活检术，统计肝硬化的发生率。结果2组治疗后肝纤维化分期及炎症活动度、肝功能和肝纤维化指标均明显改善，且治疗组改善情况明显优于对照组（P均<0.05）；治疗后治疗组 HBV DNA 转阴率及总有效率均明显高于对照组（P均<0.05），肝硬化发生率明显低于对照组（P<0.05）。结论益肾疏肝活络方联合恩替卡韦可以明显延缓和/或逆转肾虚血瘀型慢性乙肝肝纤维化的进展。
目的：觀察益腎疏肝活絡方聯閤恩替卡韋治療腎虛血瘀型慢性乙肝肝纖維化的臨床療效。方法將120例慢性乙肝肝纖維化患者隨機分為2組，治療組60例給予益腎疏肝活絡方聯閤恩替卡韋治療，對照組60例給予閤恩替卡韋，療程均為4週。2組分彆于治療前及治療24，48週後檢測 HBV DNA轉陰率、肝功能、血清肝纖維化指標、血常規、腎功能、尿常規，併于治療前及48週結束後行肝髒穿刺病理活檢術，統計肝硬化的髮生率。結果2組治療後肝纖維化分期及炎癥活動度、肝功能和肝纖維化指標均明顯改善，且治療組改善情況明顯優于對照組（P均<0.05）；治療後治療組 HBV DNA 轉陰率及總有效率均明顯高于對照組（P均<0.05），肝硬化髮生率明顯低于對照組（P<0.05）。結論益腎疏肝活絡方聯閤恩替卡韋可以明顯延緩和/或逆轉腎虛血瘀型慢性乙肝肝纖維化的進展。
목적：관찰익신소간활락방연합은체잡위치료신허혈어형만성을간간섬유화적림상료효。방법장120례만성을간간섬유화환자수궤분위2조，치료조60례급여익신소간활락방연합은체잡위치료，대조조60례급여합은체잡위，료정균위4주。2조분별우치료전급치료24，48주후검측 HBV DNA전음솔、간공능、혈청간섬유화지표、혈상규、신공능、뇨상규，병우치료전급48주결속후행간장천자병리활검술，통계간경화적발생솔。결과2조치료후간섬유화분기급염증활동도、간공능화간섬유화지표균명현개선，차치료조개선정황명현우우대조조（P균<0.05）；치료후치료조 HBV DNA 전음솔급총유효솔균명현고우대조조（P균<0.05），간경화발생솔명현저우대조조（P<0.05）。결론익신소간활락방연합은체잡위가이명현연완화/혹역전신허혈어형만성을간간섬유화적진전。
Objective It is to observe the clinical effect of Yishen Shugan Tongluo Recipe( YSTR)combined with ente-cavir in treatment of chronic hepatitis B hepatic fibrosis of kidney deficiency and blood stasis type. Methods 120 patients with chronic hepatitis B hepatic fibrosis were divided into two groups,60 cases in the treatment group were treated with YSTR com-bined with entecavir,60 cases in the control group were treated with entecavir only,the course of treatment was 4 weeks. Be-fore treatment and after 24 weeks and 48 weeks of treatment,the HBV DNA negative rate,liver function( ALT,AST),serum liver fibrosis indexes( HA,Ⅳ -C,PCⅢ,LN),blood routine,renal function,urine routine were detected. Before treatment and after treatment for 48 week,the liver biopsy,the incidences of cirrhosis of the liver were observed. Results The hepatic fi-brosis staging and inflammation activity,liver function and the index of hepatic fibrosis and cirrhosis of the liver were signifi-cantly improved(all P<0. 05),and that of the treatment group were improved significantly better than the control group(all P<0. 05). The HBV DNA negative rate and the total effective rate of treatment group were higher than those of control group (all P<0. 05),and the rate of liver cirrhosis of treatment group was lower than that of control group(P<0. 05). Conclusion YSTR combined with entecavir can obviously delay and / or reverse the progress of chronic hepatitis B liver fibrosis reversal of kidney deficiency and blood stasis type.
